Skip to main content
SpringerLink
Log in

The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage. Two retrospective studies, each with methodologic limitations, provide conflicting advice regarding treatment. This single-institution retrospective study was conducted to determine survival trends in patients with AA. All patients ≥18 years with newly-diagnosed AA treated at Johns Hopkins from 1995 to 2012 were included. As we incorporated TMZ into high-grade glioma treatment regimens in 2004, patients were divided into pre-2004 and post-2004 groups for analysis. Clinical, radiographic, and pathologic data were collected. Median overall survival (OS) was calculated using Kaplan–Meier estimates. A total of 196 patients were identified; 74 pre-2004 and 122 post-2004; mean age 47 ± 15 years; 57 % male; 87 % white, 69 % surgical debulking. Mean RT dose 5676 + 746 cGy; duration of concurrent chemoradiation 5.8 ± 0.8 weeks; and mean adjuvant chemotherapy 4.3 + 2.8 cycles. Baseline prognostic factors did not differ between groups. Chemotherapy was administered to 12 % of patients pre-2004 (TMZ = 1, procarbazine, lomustine and vincristine = 2, carmustine wafer = 6) and 94 % post-2004 (TMZ in all, p < 0.001). Median OS was 32 months (95 % CI 23–43). Survival was longer in the post-2004 cohort (37 mo, 24–64) than pre-2004 (27 mo, 19–40; HR 0.75, 0.53–1.06, p = 0.11). Multivariate analysis controlling for age, Karnofsky performance status, and extent of resection revealed a 36 % reduced risk of death (HR 0.64, 0.44–0.91, p = 0.015) in patients treated post-2004. This retrospective review found survival in newly diagnosed patients with AA improved with the addition of temozolomide to standard radiation. Until prospective randomized phase III data are available, these data support the practice of incorporating TMZ in the management of newly-diagnosed AA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dolecek TA, Propp JM, NE Stroup, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:v1–v49

    Article  PubMed Central  PubMed  Google Scholar 

  2. Stupp R, Mason W, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 352:987–996

    Article  CAS  PubMed  Google Scholar 

  3. Chang SM, Parney IF, Huang W, Anderson FA, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557–564

    Article  CAS  PubMed  Google Scholar 

  4. Ray S, Bonafede MM, Mohile NA (2014) Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am Health Drug Benefits 7(3):140–149

    PubMed Central  PubMed  Google Scholar 

  5. Weller M, van den Bent M, Hopkins K et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395–e403

    Article  PubMed  Google Scholar 

  6. Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Van Den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350

    Article  PubMed  Google Scholar 

  8. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880

    Article  CAS  PubMed  Google Scholar 

  9. Scoccianti S, Magrini SM, Ricardi U et al (2012) Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol 14:798–807

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Shonka NA, Theeler B, Cahill D, Yung A, Smith L, Lei X, Gilbert MR (2013) Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol 113:305–311

    Article  CAS  PubMed  Google Scholar 

  11. Kalbfleisch J, Prentice R (2002) The statistical analysis of failure time data. Wiley, Hoboken

    Book  Google Scholar 

  12. Cox DR, Society S, Methodological SB (2007) regression models and life-tables. J R Stat Soc Ser B 34:187–220

    Google Scholar 

  13. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722

    Article  CAS  PubMed  Google Scholar 

  15. Prados BMD, Scott C, Curran WJ, Nelson DF, Leibel S, Kramer S (2007) anaplastic astrocytoma: a retrospective review of radiation carmustine or PCV adjuvant chemotherapy. Society 17:3389–3395

    Google Scholar 

  16. Brandes AA, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, Reni M, Rotilio A, Sotti G, Ermani M (2006) Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 8:253–260

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ (2008) Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer 44:1210–1216

    Article  CAS  PubMed  Google Scholar 

  18. Hildebrand J, Sahmoud T, Mignolet F, Brucher J, Afra D (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 44:1479–1483

    CAS  PubMed  Google Scholar 

  19. Brada M, Ashley S, Dowe A et al (2005) Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 16:942–949

    Article  CAS  PubMed  Google Scholar 

  20. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 4:261–267

    PubMed Central  CAS  PubMed  Google Scholar 

  21. Yung BWKA, Prados MD, Yaya-tur R et al (2015) With anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762–2771

    Google Scholar 

  22. Armstrong TS, Cao Y, Scheurer ME, Vera-Bolaños E, Manning R, Okcu MF, Bondy M, Zhou R, Gilbert MR (2009) Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol 11:825–832

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Gerber DE, Grossman S, Zeltzman M, Parisi M, Kleinberg L (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47–52

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Rogers G, Garside R, Mealing S, Pitt M, Anderson R, Dyer M, Stein K, Somerville M (2008) Carmustine implants for the treatment of newly diagnosed high-grade gliomas. Pharmacoeconomics 26:33–44

    Article  PubMed  Google Scholar 

  25. Johnson BE, Mazor T, Hong C et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189–193

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, Laack NN, Parney IF, Uhm JH, Buckner JC (2014) The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. J Neurooncol 120:85–93

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Van Den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120:297–304

    Article  PubMed Central  PubMed  Google Scholar 

  28. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443–2449

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Funding

This study received no internal or external funding.

Author information

Authors and Affiliations

  1. Department of Neurology, Johns Hopkins School of Medicine, Cancer Research Building II, 1550 Orleans St, Baltimore, MD, 21287, USA

    Roy E. Strowd

  2. Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD, 21287, USA

    Inas Abuali

  3. Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA

    Xiaobu Ye & Yao Lu

  4. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA

    Stuart A. Grossman

Authors
  1. Roy E. Strowd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inas Abuali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaobu Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stuart A. Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roy E. Strowd.

Ethics declarations

Conflicts of Interest

Dr. Strowd reports no disclosures or conflicts of interest. Dr. Abuali reports no disclosures or conflicts of interest. Ms. Lu reports no disclosures or conflicts of interest. Dr. Ye reports no disclosures or conflicts of interest. Dr. Grossman reports no disclosures or conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 1210 kb)

Supplementary material 2 (TIFF 974 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strowd, R.E., Abuali, I., Ye, X. et al. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. J Neurooncol 127, 165–171 (2016). https://doi.org/10.1007/s11060-015-2028-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-2028-2

Keywords

Search

Navigation